Keymed Biosciences Inc.

SEHK:2162 Stock Report

Market Cap: HK$8.8b

Keymed Biosciences Future Growth

Future criteria checks 2/6

Keymed Biosciences is forecast to grow earnings and revenue by 13.8% and 50.3% per annum respectively. EPS is expected to grow by 14.6% per annum. Return on equity is forecast to be -49.6% in 3 years.

Key information

13.8%

Earnings growth rate

14.6%

EPS growth rate

Biotechs earnings growth43.4%
Revenue growth rate50.3%
Future return on equity-49.6%
Analyst coverage

Good

Last updated24 Dec 2024

Recent future growth updates

Keymed Biosciences Inc. (HKG:2162) Just Reported And Analysts Have Been Cutting Their Estimates

Mar 31
Keymed Biosciences Inc. (HKG:2162) Just Reported And Analysts Have Been Cutting Their Estimates

Recent updates

Health Check: How Prudently Does Keymed Biosciences (HKG:2162) Use Debt?

Oct 21
Health Check: How Prudently Does Keymed Biosciences (HKG:2162) Use Debt?

There's Reason For Concern Over Keymed Biosciences Inc.'s (HKG:2162) Massive 28% Price Jump

May 13
There's Reason For Concern Over Keymed Biosciences Inc.'s (HKG:2162) Massive 28% Price Jump

News Flash: 10 Analysts Think Keymed Biosciences Inc. (HKG:2162) Earnings Are Under Threat

Apr 03
News Flash: 10 Analysts Think Keymed Biosciences Inc. (HKG:2162) Earnings Are Under Threat

Keymed Biosciences Inc. (HKG:2162) Just Reported And Analysts Have Been Cutting Their Estimates

Mar 31
Keymed Biosciences Inc. (HKG:2162) Just Reported And Analysts Have Been Cutting Their Estimates

A Look At The Intrinsic Value Of Keymed Biosciences Inc. (HKG:2162)

Nov 13
A Look At The Intrinsic Value Of Keymed Biosciences Inc. (HKG:2162)

Analysts Just Made A Noticeable Upgrade To Their Keymed Biosciences Inc. (HKG:2162) Forecasts

Sep 03
Analysts Just Made A Noticeable Upgrade To Their Keymed Biosciences Inc. (HKG:2162) Forecasts

Broker Revenue Forecasts For Keymed Biosciences Inc. (HKG:2162) Are Surging Higher

Mar 21
Broker Revenue Forecasts For Keymed Biosciences Inc. (HKG:2162) Are Surging Higher

Companies Like Keymed Biosciences (HKG:2162) Are In A Position To Invest In Growth

Jun 27
Companies Like Keymed Biosciences (HKG:2162) Are In A Position To Invest In Growth

Earnings and Revenue Growth Forecasts

SEHK:2162 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,249-471-685-4558
12/31/2025538-789-801-7019
12/31/2024141-757-954-6319
6/30/202482-743-900-709N/A
3/31/2024218-551-767-506N/A
12/31/2023354-359-635-304N/A
9/30/2023341-313-587-250N/A
6/30/2023327-267-539-197N/A
3/31/2023214-287-610-299N/A
12/31/2022100-308-681-402N/A
9/30/2022155-281-661-349N/A
6/30/2022210-253-640-295N/A
3/31/2022160-2,070-514-255N/A
12/31/2021110-3,887-387-215N/A
9/30/202155-4,149-269-169N/A
6/30/2021N/A-4,412-150-124N/A
3/31/2021N/A-2,615-145-122N/A
12/31/2020N/A-819-139-119N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2162 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 2162 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 2162 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 2162's revenue (50.3% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).

High Growth Revenue: 2162's revenue (50.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 2162 is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 02:48
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Keymed Biosciences Inc. is covered by 19 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jin ZhangChina International Capital Corporation Limited
Ziyu HeChina International Capital Corporation Limited
Wangbin ZhouChina International Capital Corporation Limited